search
Back to results

Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders

Primary Purpose

Dementia, Neurocognitive Disorders, Cognitive Impairment

Status
Completed
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
Reminiscence therapy
Sponsored by
Rsocialform - Geriatria, Lda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dementia focused on measuring older adults, dementia, reminiscence therapy, quality of life, cognition, neurocognitive disorders, individual therapy, non-pharmacological therapy, randomised controlled trial, mood, depression, anxiety, memory

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Having a formal diagnosis of a neurocognitive disorder according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] criteria (participants diagnosis will be confirm in their health records at the institution).
  • Having delivered the informed consent form, duly completed and signed, after prior information.
  • Being able to communicate and understand.
  • Possibility of gathering information about the participant's life history through family members or usual caregivers, using the socio-family questionnaire designed for that purpose.
  • Being 65 years of age or older.
  • Being a native Portuguese speaker.
  • Regularly attending an institution that provides social care and support services for older adults (including people living in long-term care centres, people attending day and social centres and people receiving home support services).

Exclusion Criteria:

  • Suffering from an acute or severe illness that prevent participation in the intervention sessions.
  • Severe sensory and physical limitations that prevent participation.
  • Low level of consciousness and minimal attention span.
  • Presence of severe neuropsychiatric symptoms, such as agitation, psychosis, severe depressive and anxiety symptoms, apathy, or presence of uncontrolled delirium that prevent participation in the sessions.
  • Traumatic life history or marked by adverse events that discourage participation in RT sessions; history of adverse reactions during RT sessions or similar activities.
  • Have a serious or total functional dependence (assessed through the Barthel index).

Sites / Locations

  • Rsocialform - Geriatria, Lda.
  • Santa Casa da Misericórdia da Horta
  • Santa Casa da Misericórdia de Santa Cruz das Flores
  • Santa Casa da Misericórdia de Lajes do Pico
  • Santa Casa da Misericórdia da Madalena do Pico
  • Santa Casa da Misericórdia de Vila do Porto
  • Santa Casa da Misericórdia da Calheta
  • Casa de Repouso João Inácio de Sousa
  • Casa do Povo de Arrifes
  • Casa do Povo da Maia
  • Lar Luis Soares de Sousa de Ponta Delgada
  • Santa Casa da Misericórdia de Angra do Heroísmo
  • Lar D. Pedro V

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Group

Control Group

Arm Description

Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.

Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.

Outcomes

Primary Outcome Measures

Cognitive functioning evaluated through Mini-Mental State Examination [MMSE]
Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.
Change in cognitive functioning evaluated through Mini-Mental State Examination [MMSE]
Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.
Change in cognitive functioning evaluated through Mini-Mental State Examination [MMSE]
Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

Secondary Outcome Measures

Quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD]
The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.
Change in quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD]
The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.
Change in quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD]
The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.
Anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI]
It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.
Change in anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI]
It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.
Change in anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI]
It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.
Mood assessed through the Geriatric Depression Scale-15 [GDS-15]
The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.
Change in mood assessed through the Geriatric Depression Scale-15 [GDS-15]
The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.
Change in mood assessed through the Geriatric Depression Scale-15 [GDS-15]
The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.
Executive functions evaluated throught Frontal Assessment Battery [FAB]
The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.
Change in executive functions evaluated throught Frontal Assessment Battery [FAB]
The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.
Change in executive functions evaluated throught Frontal Assessment Battery [FAB]
The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.
Memory function evaluated through Memory Alteration Test [MAT]
The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.
Change in memory function evaluated through Memory Alteration Test [MAT]
The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.
Change in memory function evaluated through Memory Alteration Test [MAT]
The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

Full Information

First Posted
November 24, 2020
Last Updated
August 31, 2021
Sponsor
Rsocialform - Geriatria, Lda
search

1. Study Identification

Unique Protocol Identification Number
NCT04658394
Brief Title
Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders
Official Title
Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders: A Multicentre Randomised Controlled Trial in Azores Archipelago
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
February 11, 2021 (Actual)
Primary Completion Date
August 31, 2021 (Actual)
Study Completion Date
August 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rsocialform - Geriatria, Lda

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This research aims to evaluate the ability of individual reminiscence therapy (RT), using a simple reminiscence format, to improve the overall cognitive function, memory, emotional status and quality of life (QoL) of older adults with neurocognitive disorders (NCD) attending social care and support services. A multicentre randomised controlled trial (RCT) is proposed in Azores archipelago with repeated measures (pre-intervention, post-intervention and follow-up). Intervention group will hold 26 individual RT sessions, twice a week for 13 weeks. Control group participants will maintain their treatment as usual. Make a subsample analysis of the main clinical diagnoses, and compare the results of sample and subsample with a previous study that had the same intervention protocol.
Detailed Description
Neurocognitive disorder (NCD) is one of the main causes of disability among older adults and its prevalence is increasing due to the ageing of the population. It is estimated that globally, neurocognitive disorders affect 44.35 million people and it is expected that by the year 2050 the number of those affected worldwide will triple up to 135.46 million. The absence of an effective pharmacological treatment that halts or delays the development of the disease has aroused interest in non-pharmacological therapies (NPT) as a complement to pharmacological treatment that can improve the quality of life of people with neurocognitive disorders. One of the most researched NPT and with the greatest tradition in this field is Reminiscence Therapy (RT). RT implies the discussion of past activities, events and experiences, usually with the help of triggers (e.g., photographs, home objects and other familiar items from the past, music, any object or stimulus) that serve to stimulate memories. In its application to dementias, RT is based on the fact that the memory deficit of people with dementia implies that they are able to remember events from their past life, especially from childhood to early adulthood, but not newer facts. It focuses on preserved capacities and memories, promotes communication and enables the person to connect with his past and recover his sense of personal identity. In this way, the RT can be understood as an intervention on the edge of those of cognitive orientation and those centred on emotion, with potential interactive effects on autobiographical memory and psychological well-being. In simplified form, there are at least two approaches to RT. The first approach as a "life review" where participants are guided through significant experiences of their biography trying to give meaning to their lives. This type of RT is more structured and is usually conducted in an individual format. It may involve the production of "life books". This approach is considered to have an integrative function aimed at achieving a sense of validation, coherence and reconciliation with one's past. Another approach that call general or simple reminiscence, implies the stimulation of autobiographical memory during conversations on specific themes of the past (e.g, holidays, food and drink, work) using stimulus to trigger memories. It has been described as an unstructured autobiographical memory narration. This reminiscence format can be conducted both individually and in groups and promotes communication between participants who share their memories and stories. In either format that RT is applied on, the introduction of triggering stimulus (e.g., photographs, music, old objects) to help memory is considered fundamental. These triggers can be generic, reflecting common experiences in the lives of people relevant to their age group (e.g., a school manual can serve as a reminder of the experience during their school stage), or specific, with stimulus related to the person's own experiences (e.g., photographs of an important vital event such as their wedding day or a journey during their youth). As for the effectiveness of RT, according to a recent review by Cochrane, there is some evidence on its positive effects on cognition, QoL, communication and possibly on the mood of people with dementia, even if the benefits are small. Despite the distinction between the two different approaches to RT (general reminiscence vs. life history), the therapy modality does not seem to be as important to achieve positive effects as the individual or group format of the sessions and the context in which the intervention is administered (people living in the community or institutionalised). In particular, according to the results of the review study, the RT seems to be able to generate a small benefit on cognitive function immediately after the intervention, although it usually does not continue after a longer follow-up period. Regarding the administration format, the individual RT seems slightly superior in its effects on cognition both immediately and after a follow-up period. In any case, its effects seem comparable to those of other cognitive stimulation modalities. As for the effect of RT on quality of life (QoL), an individual RT study based on life review, showed an improvement in Qol-AD. The effects with a group modality do not seem consistent, showing little or no effect on QoL, although the key factor may be the context of application (community vs. institution), with better group RT results in institutionalised patients. In a multicentre study conducted in Portugal with older adults with neurocognitive disorders, in individual format, there was a significant effect on the overall cognition, memory and QoL of the participants. Group RT was associated with a likely effect on communication both after the intervention and in the follow-up. This effect was not replicated in the individual RT, with uncertain results. Finally, despite the evidence on the effect of RT on the mood of elderly people without dementia, in the case of people with dementia only a small effect on mood was found for those participating in individual RT. In the portuguese multicentre studies there were no significant differences in depressive symptomatology. Based on the above, this research proposal aims to evaluate the ability of individual RT within a general reminiscence format, to improve overall cognitive function, in particular memory, emotional state (depression and anxiety) and QoL of older adults with neurocognitive disorders attending social care and support services in the Azores archipelago. It is proposed to evaluate the efficacy of the intervention in the endpoint assessment and the duration of the effects at three months follow-up. Furthermore, an analysis of results based on the diagnosis of the participants is proposed for those diagnoses with sufficient representation in the sample (more than 20 cases in each group). Additionally, it is proposed to analyze the factors that predict the response to the intervention (responder analysis). Finally, the results of this study will be compared and can be analyzed together with those of a previous study that used the same individual RT program and the same experimental design (clinicaltrials.gov ID: NCT04047238).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia, Neurocognitive Disorders, Cognitive Impairment, Cognitive Dysfunction, Cognitive Decline
Keywords
older adults, dementia, reminiscence therapy, quality of life, cognition, neurocognitive disorders, individual therapy, non-pharmacological therapy, randomised controlled trial, mood, depression, anxiety, memory

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
122 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
Intervention Type
Other
Intervention Name(s)
Reminiscence therapy
Intervention Description
Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
Primary Outcome Measure Information:
Title
Cognitive functioning evaluated through Mini-Mental State Examination [MMSE]
Description
Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.
Time Frame
baseline
Title
Change in cognitive functioning evaluated through Mini-Mental State Examination [MMSE]
Description
Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.
Time Frame
13 weeks after the beginning of the intervention
Title
Change in cognitive functioning evaluated through Mini-Mental State Examination [MMSE]
Description
Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.
Time Frame
12 weeks after end of intervention
Secondary Outcome Measure Information:
Title
Quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD]
Description
The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.
Time Frame
baseline
Title
Change in quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD]
Description
The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.
Time Frame
13 weeks after the beginning of the intervention
Title
Change in quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD]
Description
The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.
Time Frame
12 weeks after end of intervention
Title
Anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI]
Description
It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.
Time Frame
baseline
Title
Change in anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI]
Description
It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.
Time Frame
13 weeks after the beginning of the intervention
Title
Change in anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI]
Description
It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.
Time Frame
12 weeks after end of intervention
Title
Mood assessed through the Geriatric Depression Scale-15 [GDS-15]
Description
The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.
Time Frame
baseline
Title
Change in mood assessed through the Geriatric Depression Scale-15 [GDS-15]
Description
The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.
Time Frame
13 weeks after the beginning of the intervention
Title
Change in mood assessed through the Geriatric Depression Scale-15 [GDS-15]
Description
The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.
Time Frame
12 weeks after end of intervention
Title
Executive functions evaluated throught Frontal Assessment Battery [FAB]
Description
The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.
Time Frame
baseline
Title
Change in executive functions evaluated throught Frontal Assessment Battery [FAB]
Description
The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.
Time Frame
13 weeks after the beginning of the intervention
Title
Change in executive functions evaluated throught Frontal Assessment Battery [FAB]
Description
The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.
Time Frame
12 weeks after end of intervention
Title
Memory function evaluated through Memory Alteration Test [MAT]
Description
The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.
Time Frame
baseline
Title
Change in memory function evaluated through Memory Alteration Test [MAT]
Description
The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.
Time Frame
13 weeks after the beginning of the intervention
Title
Change in memory function evaluated through Memory Alteration Test [MAT]
Description
The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.
Time Frame
12 weeks after end of intervention
Other Pre-specified Outcome Measures:
Title
Sociodemographic information gathered through the sociodemographic questionnaire
Description
Participants' answers in the sociodemographic questionnaire designed specifically for this study. It gathers information about gender, age, marital status, formal education, which social response the participant attends, medical comorbidities and cognitive symptoms and will be administered to all participants.
Time Frame
baseline
Title
Functional dependence evaluated through Barthel Index [IB]
Description
This is a 10-item self-administered scale that evaluates the functional capacity to conduct daily life activities. The activities are quoted differently, 0, 1, 2 or 3 points can be assigned. The total score ranges from 0 (totally dependent) to 20 (totally independent), with a total of 0-8 being total dependency; 9-12 being serious dependency; 13-19 being moderate dependency; 20 being total independence. This instrument has item-total correlations between .66 and .93, and has a high internal consistency (Cronbach alpha of .96).
Time Frame
before baseline (exclusion criteria)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Having a formal diagnosis of a neurocognitive disorder according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] criteria (participants diagnosis will be confirm in their health records at the institution). Having delivered the informed consent form, duly completed and signed, after prior information. Being able to communicate and understand. Possibility of gathering information about the participant's life history through family members or usual caregivers, using the socio-family questionnaire designed for that purpose. Being 65 years of age or older. Being a native Portuguese speaker. Regularly attending an institution that provides social care and support services for older adults (including people living in long-term care centres, people attending day and social centres and people receiving home support services). Exclusion Criteria: Suffering from an acute or severe illness that prevent participation in the intervention sessions. Severe sensory and physical limitations that prevent participation. Low level of consciousness and minimal attention span. Presence of severe neuropsychiatric symptoms, such as agitation, psychosis, severe depressive and anxiety symptoms, apathy, or presence of uncontrolled delirium that prevent participation in the sessions. Traumatic life history or marked by adverse events that discourage participation in RT sessions; history of adverse reactions during RT sessions or similar activities. Have a serious or total functional dependence (assessed through the Barthel index).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susana I Justo Henriques, PhD
Organizational Affiliation
Nursing School of Coimbra
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Enrique Pérez Sáez, PhD
Organizational Affiliation
National Reference Centre for Alzheimer's and Dementia Care, Imserso, Spain
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
João L. Alves Apóstolo, PhD
Organizational Affiliation
Nursing School of Coimbra
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rsocialform - Geriatria, Lda.
City
Mealhada
State/Province
Aveiro
ZIP/Postal Code
3050-387
Country
Portugal
Facility Name
Santa Casa da Misericórdia da Horta
City
Horta
State/Province
Faial
ZIP/Postal Code
9900-033
Country
Portugal
Facility Name
Santa Casa da Misericórdia de Santa Cruz das Flores
City
Santa Cruz das Flores
State/Province
Flores
Country
Portugal
Facility Name
Santa Casa da Misericórdia de Lajes do Pico
City
Lajes
State/Province
Pico
ZIP/Postal Code
9930-126
Country
Portugal
Facility Name
Santa Casa da Misericórdia da Madalena do Pico
City
Madalena
State/Province
Pico
ZIP/Postal Code
9950-322
Country
Portugal
Facility Name
Santa Casa da Misericórdia de Vila do Porto
City
Vila do Porto
State/Province
Santa Maria
ZIP/Postal Code
9580-528
Country
Portugal
Facility Name
Santa Casa da Misericórdia da Calheta
City
Calheta
State/Province
São Jorge
ZIP/Postal Code
9850-070
Country
Portugal
Facility Name
Casa de Repouso João Inácio de Sousa
City
Velas
State/Province
São Jorge
ZIP/Postal Code
9800-559
Country
Portugal
Facility Name
Casa do Povo de Arrifes
City
Arrifes
State/Province
São Miguel
ZIP/Postal Code
9500-377
Country
Portugal
Facility Name
Casa do Povo da Maia
City
Maia
State/Province
São Miguel
ZIP/Postal Code
9625-320
Country
Portugal
Facility Name
Lar Luis Soares de Sousa de Ponta Delgada
City
Ponta Delgada
State/Province
São Miguel
Country
Portugal
Facility Name
Santa Casa da Misericórdia de Angra do Heroísmo
City
Angra Do Heroísmo
State/Province
Terceira
ZIP/Postal Code
9700-020
Country
Portugal
Facility Name
Lar D. Pedro V
City
Praia Da Vitória
State/Province
Terceira
ZIP/Postal Code
9760-438
Country
Portugal

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21543189
Citation
Akanuma K, Meguro K, Meguro M, Sasaki E, Chiba K, Ishii H, Tanaka N. Improved social interaction and increased anterior cingulate metabolism after group reminiscence with reality orientation approach for vascular dementia. Psychiatry Res. 2011 Jun 30;192(3):183-7. doi: 10.1016/j.pscychresns.2010.11.012. Epub 2011 May 4.
Results Reference
background
PubMed Identifier
26572551
Citation
Amieva H, Robert PH, Grandoulier AS, Meillon C, De Rotrou J, Andrieu S, Berr C, Desgranges B, Dubois B, Girtanner C, Joel ME, Lavallart B, Nourhashemi F, Pasquier F, Rainfray M, Touchon J, Chene G, Dartigues JF. Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. Int Psychogeriatr. 2016 May;28(5):707-17. doi: 10.1017/S1041610215001830. Epub 2015 Nov 17.
Results Reference
background
Citation
Apóstolo JLA, Bobrowicz-Campos EM, dos Reis IAC, Henriques SJ, Correia CAV. Exploring the screening capacity of the European Portuguese version of the 15-item Geriatric Depression Scale. Revista de Psicopatología y Psicología Clínica. 2018; 23: 99-107. doi: 10.5944/rppc.vol.23.num.2.2018.21050
Results Reference
background
Citation
Apóstolo J, Loureiro L, Reis I, Silva I, Cardoso D, Sfetcu R. Contribution to the adaptation of the Geriatric Depression Scale -15 into Portuguese. Revista de Enfermagem Referência. 2014; IV(3): 65-73. doi: 10.12707/RIV14033
Results Reference
background
Citation
Araújo F, Pais-Ribeiro J, Oliveira A, Pinto C. Validação do índice de Barthel numa amostra de idosos não institucionalizados. Revista Portuguesa de Saúde Pública. 2007; 25(2): 59-66.
Results Reference
background
PubMed Identifier
23429813
Citation
Serrani Azcurra DJ. A reminiscence program intervention to improve the quality of life of long-term care residents with Alzheimer's disease: a randomized controlled trial. Braz J Psychiatry. 2012 Dec;34(4):422-33. doi: 10.1016/j.rbp.2012.05.008.
Results Reference
background
PubMed Identifier
23534370
Citation
Barrios H, Verdelho A, Narciso S, Goncalves-Pereira M, Logsdon R, de Mendonca A. Quality of life in patients with cognitive impairment: validation of the Quality of Life-Alzheimer's Disease scale in Portugal. Int Psychogeriatr. 2013 Jul;25(7):1085-96. doi: 10.1017/S1041610213000379. Epub 2013 Mar 27.
Results Reference
background
PubMed Identifier
19896760
Citation
Caddell LS, Clare L. The impact of dementia on self and identity: a systematic review. Clin Psychol Rev. 2010 Feb;30(1):113-26. doi: 10.1016/j.cpr.2009.10.003.
Results Reference
background
PubMed Identifier
27521377
Citation
Charlesworth G, Burnell K, Crellin N, Hoare Z, Hoe J, Knapp M, Russell I, Wenborn J, Woods B, Orrell M. Peer support and reminiscence therapy for people with dementia and their family carers: a factorial pragmatic randomised trial. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1218-1228. doi: 10.1136/jnnp-2016-313736. Epub 2016 Aug 12.
Results Reference
background
PubMed Identifier
24599812
Citation
Dempsey L, Murphy K, Cooney A, Casey D, O'Shea E, Devane D, Jordan F, Hunter A. Reminiscence in dementia: a concept analysis. Dementia (London). 2014 Mar 1;13(2):176-92. doi: 10.1177/1471301212456277. Epub 2012 Aug 17.
Results Reference
background
PubMed Identifier
1202204
Citation
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
Results Reference
background
PubMed Identifier
25531579
Citation
Freitas S, Simoes MR, Alves L, Santana I. The Relevance of Sociodemographic and Health Variables on MMSE Normative Data. Appl Neuropsychol Adult. 2015;22(4):311-9. doi: 10.1080/23279095.2014.926455. Epub 2014 Dec 22.
Results Reference
background
PubMed Identifier
25765779
Citation
Gonzalez J, Mayordomo T, Torres M, Sales A, Melendez JC. Reminiscence and dementia: a therapeutic intervention. Int Psychogeriatr. 2015 Oct;27(10):1731-7. doi: 10.1017/S1041610215000344. Epub 2015 Mar 13.
Results Reference
background
Citation
Guerreiro M, Silva AP, Botelho MA, Leitão O, Castro-Caldas A, Garcia C. Adaptação à população portuguesa da tradução do Mini Mental State Examination (MMSE). Revista Portuguesa de Neurologia. 1994; 1: 9-10.
Results Reference
background
PubMed Identifier
19595856
Citation
Haight BK, Gibson F, Michel Y. The Northern Ireland life review/life storybook project for people with dementia. Alzheimers Dement. 2006 Jan;2(1):56-8. doi: 10.1016/j.jalz.2005.12.003.
Results Reference
background
Citation
Henriques SIJ. Livro do Passado e do Presente [Book of the Past and the Present]. Mealhada, Replicar Socialform; 2018.
Results Reference
background
PubMed Identifier
33176394
Citation
Justo-Henriques SI, Perez-Saez E, Alves Apostolo JL. Multicentre randomised controlled trial about the effect of individual reminiscence therapy in older adults with neurocognitive disorders. Int J Geriatr Psychiatry. 2021 May;36(5):704-712. doi: 10.1002/gps.5469. Epub 2020 Nov 17.
Results Reference
background
Citation
Justo-Henriques SI, Pérez-Sáez E, Apóstolo JLA. Individual intervention protocol based on reminiscence therapy for older people with neurocognitive disorders. Revista de Enfermagem de Referência. 2020; 5(3): e20043. doi: 10.12707/RV20043
Results Reference
background
PubMed Identifier
28676268
Citation
Kirk M, Berntsen D. A short cut to the past: Cueing via concrete objects improves autobiographical memory retrieval in Alzheimer's disease patients. Neuropsychologia. 2018 Feb;110:113-122. doi: 10.1016/j.neuropsychologia.2017.06.034. Epub 2017 Jul 1.
Results Reference
background
PubMed Identifier
30198380
Citation
Kirk M, Rasmussen KW, Overgaard SB, Berntsen D. Five weeks of immersive reminiscence therapy improves autobiographical memory in Alzheimer's disease. Memory. 2019 Apr;27(4):441-454. doi: 10.1080/09658211.2018.1515960. Epub 2018 Sep 8.
Results Reference
background
PubMed Identifier
15190995
Citation
Lai CK, Chi I, Kayser-Jones J. A randomized controlled trial of a specific reminiscence approach to promote the well-being of nursing home residents with dementia. Int Psychogeriatr. 2004 Mar;16(1):33-49. doi: 10.1017/s1041610204000055.
Results Reference
background
Citation
Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: Patient and caregiver reports. Journal of Mental Health and Aging. 1999; 5: 21-32.
Results Reference
background
PubMed Identifier
14258950
Citation
MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61-5. No abstract available.
Results Reference
background
PubMed Identifier
18297476
Citation
Moniz-Cook E, Vernooij-Dassen M, Woods R, Verhey F, Chattat R, De Vugt M, Mountain G, O'Connell M, Harrison J, Vasse E, Droes RM, Orrell M; INTERDEM group. A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging Ment Health. 2008 Jan;12(1):14-29. doi: 10.1080/13607860801919850.
Results Reference
background
Citation
Morgado J, Rocha CS, Maruta C, Guerreiro M, Martins IP. Novos valores normativos do Mini-Mental State Examination. Sinapse. 2009; 2: 10-16.
Results Reference
background
PubMed Identifier
24633858
Citation
O'Shea E, Devane D, Cooney A, Casey D, Jordan F, Hunter A, Murphy E, Newell J, Connolly S, Murphy K. The impact of reminiscence on the quality of life of residents with dementia in long-stay care. Int J Geriatr Psychiatry. 2014 Oct;29(10):1062-70. doi: 10.1002/gps.4099. Epub 2014 Mar 14.
Results Reference
background
PubMed Identifier
16805925
Citation
Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E. Development and validation of the Geriatric Anxiety Inventory. Int Psychogeriatr. 2007 Feb;19(1):103-14. doi: 10.1017/S1041610206003504.
Results Reference
background
PubMed Identifier
18074252
Citation
Pinquart M, Duberstein PR, Lyness JM. Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: a meta-analysis. Aging Ment Health. 2007 Nov;11(6):645-57. doi: 10.1080/13607860701529635.
Results Reference
background
Citation
Prince M, Guerchet M, Prina M. World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends. London: Alzheimer´s Disease International (ADI); 2015. http://www.worldalzreport2015.org/downloads/world-alzheimer-report-2015.pdf
Results Reference
background
PubMed Identifier
16998781
Citation
Rami L, Molinuevo JL, Sanchez-Valle R, Bosch B, Villar A. Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Int J Geriatr Psychiatry. 2007 Apr;22(4):294-304. doi: 10.1002/gps.1672.
Results Reference
background
PubMed Identifier
21656405
Citation
Ribeiro O, Paul C, Simoes MR, Firmino H. Portuguese version of the Geriatric Anxiety Inventory: transcultural adaptation and psychometric validation. Aging Ment Health. 2011 Aug;15(6):742-8. doi: 10.1080/13607863.2011.562177. Epub 2011 Jun 9.
Results Reference
background
PubMed Identifier
24009169
Citation
Sarkamo T, Tervaniemi M, Laitinen S, Numminen A, Kurki M, Johnson JK, Rantanen P. Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized controlled study. Gerontologist. 2014 Aug;54(4):634-50. doi: 10.1093/geront/gnt100. Epub 2013 Sep 5.
Results Reference
background
Citation
Subramaniam P, Woods B. Towards the therapeutic use of information and communication technology in reminiscence work for people with dementia: a systematic review. International Journal of Computers in Healthcare. 2010; 1: 106-125. doi: 10.1504/IJCIH.2010.037457.
Results Reference
background
PubMed Identifier
22550983
Citation
Subramaniam P, Woods B. The impact of individual reminiscence therapy for people with dementia: systematic review. Expert Rev Neurother. 2012 May;12(5):545-55. doi: 10.1586/ern.12.35.
Results Reference
background
PubMed Identifier
24063317
Citation
Subramaniam P, Woods B, Whitaker C. Life review and life story books for people with mild to moderate dementia: a randomised controlled trial. Aging Ment Health. 2014;18(3):363-75. doi: 10.1080/13607863.2013.837144. Epub 2013 Sep 24.
Results Reference
background
Citation
Tadaka E, Kanagawa K. Effects of reminiscence group in elderly people with Alzheimer disease and vascular dementia in a community setting. Geriatrics & Gerontology International. 2007; 7: 167-173. doi: 10.1111/j.1447-0594.2007.00381.x
Results Reference
background
Citation
Thorgrimsen L, Schweitzer P, Orrell M. Evaluating reminiscence for people with dementia: A pilot study. The Arts in Psychotherapy. 2002; 29: 93-97. doi: 10.1016/S0197-4556(01)00135-6
Results Reference
background
Citation
Westerhof GJ, Bohlmeijer E, Webster JD. Reminiscence and mental health: A review of recent progress in theory, research and interventions. Ageing & Society. 2010; 30: 697-721. doi: 10.1017/S0144686X09990328
Results Reference
background
PubMed Identifier
1863396
Citation
Wong PT, Watt LM. What types of reminiscence are associated with successful aging? Psychol Aging. 1991 Jun;6(2):272-9. doi: 10.1037//0882-7974.6.2.272.
Results Reference
background
PubMed Identifier
29493789
Citation
Woods B, O'Philbin L, Farrell EM, Spector AE, Orrell M. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018 Mar 1;3(3):CD001120. doi: 10.1002/14651858.CD001120.pub3.
Results Reference
background
PubMed Identifier
15846613
Citation
Woods B, Spector A, Jones C, Orrell M, Davies S. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001120. doi: 10.1002/14651858.CD001120.pub2.
Results Reference
background
PubMed Identifier
23211271
Citation
Woods RT, Bruce E, Edwards RT, Elvish R, Hoare Z, Hounsome B, Keady J, Moniz-Cook ED, Orgeta V, Orrell M, Rees J, Russell IT. REMCARE: reminiscence groups for people with dementia and their family caregivers - effectiveness and cost-effectiveness pragmatic multicentre randomised trial. Health Technol Assess. 2012;16(48):v-xv, 1-116. doi: 10.3310/hta16480.
Results Reference
background
PubMed Identifier
19642992
Citation
Woods RT, Bruce E, Edwards RT, Hounsome B, Keady J, Moniz-Cook ED, Orrell M, Russell IT. Reminiscence groups for people with dementia and their family carers: pragmatic eight-centre randomised trial of joint reminiscence and maintenance versus usual treatment: a protocol. Trials. 2009 Jul 30;10:64. doi: 10.1186/1745-6215-10-64.
Results Reference
background
PubMed Identifier
7183759
Citation
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49. doi: 10.1016/0022-3956(82)90033-4.
Results Reference
background
PubMed Identifier
18821046
Citation
Lima CF, Meireles LP, Fonseca R, Castro SL, Garrett C. The Frontal Assessment Battery (FAB) in Parkinson's disease and correlations with formal measures of executive functioning. J Neurol. 2008 Nov;255(11):1756-61. doi: 10.1007/s00415-008-0024-6. Epub 2008 Sep 25.
Results Reference
background
PubMed Identifier
11113214
Citation
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-6. doi: 10.1212/wnl.55.11.1621.
Results Reference
background
PubMed Identifier
33467972
Citation
Perez-Saez E, Justo-Henriques SI, Alves Apostolo JL. Multicenter randomized controlled trial of the effects of individual reminiscence therapy on cognition, depression and quality of life: Analysis of a sample of older adults with Alzheimer's disease and vascular dementia. Clin Neuropsychol. 2022 Oct;36(7):1975-1996. doi: 10.1080/13854046.2021.1871962. Epub 2021 Jan 19.
Results Reference
background

Learn more about this trial

Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders

We'll reach out to this number within 24 hrs